BioInformant

Your Global Leader in Stem Cell Market Research

You are here: Home / Archives for clinical trials

Stem Cell Clinical Trials – How to Find One for Your Condition?

By

Stem cell clinical trials are research studies that involves human patients. Learn a simple tool to identify stem cell clinical trials for your condition.

Are you or a loved on suffering from arthritis, multiple sclerosis (MS), Alzheimer’s disease, dementia, or other chronic condition? If so, how do you find a stem cell clinical trial? This is a question that we get asked on a regular basis by readers of our site.

This article provides all the answers, including links to global registries to find a trial within your region and direct links to clinical trials by condition.

Use this guide to get started with your search for a stem cell clinical trial near you.

[Read more…]

Geographic “Hotspots” for Exosome Clinical Trials

By

As exosomes become recognized for their benefits as cell-free therapeutics, exosome clinical trials are increasing in number. Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, altering the function of target cells.

Exosome Clinical Trials

In addition to increasing in number, exosome clinical trials are tightly concentrated within specific regions of the world.

There are now 92 trials listed on ClinicalTrials.gov that contain the term “exosome” or “exosomes.” [Read more…]

Exopharm to commercialize a new type of nano-drug for regenerative medicine

By

May 5, 2017, Melbourne, Australia — A private Australian biotechnology company called Exopharm has announced its investment to bring a completely new type of drug called exosomes into local clinical trials.

Exopharm is founded and backed by Dr Ian Dixon, the Melbourne-based technology innovator behind an ASX-listed cell therapy company, the anisina anticancer drug and the Altnia Group incubator. After more than 3 years of secret R&D, Altnia is spinning Exopharm out as a specialist company to translate the promising scientific research around exosomes into routine clinical use worldwide for regenerative medicine. Exopharm will build on its patented purification technology called LEAP to make its proprietary exomeres in large scale and at low cost. [Read more…]

Clinical Trials Investigating Cord Tissue Derived Mesenchymal Stem Cells (CT-MSCs)

By

Currently, there are a number of clinical trials that are investigating the therapeutic potential of mesenchymal stem cells derived from umbilical cord tissue, often called Wharton’s Jelly.

Specific conditions that have been or are now being researched for their potential to be treated with stem cells derived from cord tissue include:

  • Cartilage repair
  • Diabetes
  • Heart disease
  • Human Immunodeficiency Virus (HIV)
  • Liver disease
  • Stroke
  • Serious wounds
  • Spinal Cord Injury

Clinical trials currently listed as involving the use of cord-tissue derived mesenchymal stem cells include:

  1. “Intracoronary or Intravenous Infusion Human Wharton’ Jelly-derived Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy”
  2. “Intracoronary Human Wharton’s Jelly- Derived Mesenchymal Stem Cells (WJ-MSCs) Transfer in Patients With Acute Myocardial Infarction (AMI)”

To search for more clinical trials using CT-MSCs, head to ClinicalTrials.gov and search for the following terms: 

  • “Wharton’s Jelly” AND “Mesenchymal Stem Cell”
  • “Wharton’s Jelly” AND “Mesenchymal Stem Cells”
  • “Umbilical Cord Tissue” AND “Mesenchymal Stem Cell”
  • “Umbilical Cord Tissue” AND “Mesenchymal Stem Cells”

ClinicalTrials.gov is website maintained by the U.S. National Institutes of Health (NIH) that is a “registry and results database of publicly and privately supported clinical studies of human participants from around the world.” While an excellent resource, it does not include all clinical trials worldwide, including some which may be listed on international registries.  

These searches will capture clinical trials that use varied vocabulary, as well as both singular and plural descriptions of the cell type. Other searches may be effective as well.

Neonatal Sources of Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) can also be derived from other tissue sources besides the newborn umbilical cord.

Specifically, MSCs can be derived from adult sources that include adipose tissue, peripheral blood, and bone marrow, as well as from neonatal tissues that include parts of the placenta and umbilical cord, as explored in the image below. This is significant because pre-clinical and clinical advances with the use of MSCs derived from other sources than cord tissue will create a greater willingness to explore medical applications for cord tissue-derived MSCs.

IMAGE.  SOURCES OF MESENCHYMAL STEM CELLS

SOURCES OF MESENCHYMAL STEM CELLS

About Us

BioInformant is the first and only market research firm to specialize in the stem cell industry. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant has been featured on news outlets including the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine. 

Breakdown of Mesenchymal Stem Cell Clinical Trials, by Phase, Geography, Sponsors, and More

By

Historical Number of Mesenchymal Stem Cell Clinical Trials (IFCB)

In 2014, the International Federation for Cell Biology (IFCB) conducted an analysis of mesenchymal stem cell clinical trials, identifying that 313 clinical trials involved mesenchymal stem cells (MSCs). The majority of these clinical trials (41.7%) were in Phase I/II. Another  23.7% of these studies were in Phase II. However, only 4.2% of these clinical trials had progressed to Phase III. As such, it is clear that the bulk of MSC clinical trials remain in the early stages of development.

Among the clinical trials that progressed through Phase III, one of the most promising stem cell therapies to emerge was Prochymal, an allogenic mesenchymal stem cell therapy derived from the bone marrow of adult donors and made by Osiris Therapeutics. Prochymal is produced by purifying MSCs from the bone marrow of donors, then culturing and packaging the cells, allowing up to 10,000 doses to be derived from a single donor.  [Read more…]

BioInformant's World-Class Clients